Zhongsheng Pharmaceutical's Subsidiary Zhongsheng Ruichuang Announces Phase II Clinical Trial Results of RAY1225 for Overweight and Obesity in Chinese Adults

Source: Shanghai Securities News · China Securities Network

Shanghai Securities News China Securities Network (Reporter Kong Lingyi) On June 8, the reporter learned fromZhongsheng PharmaceuticalAccording to the official WeChat account of Raynovent, a subsidiary of Zhongsheng Pharmaceutical, the 86th Scientific Sessions of the American Diabetes Association (ADA) were recently held. At the conference, RAY1225, a globally first-in-class, fully biased GLP-1/GIP receptor agonist developed independently by Raynovent with a biweekly dosing regimen, presented the results of its Phase II clinical study (REBUILDING-1) for the treatment of overweight or obesity in Chinese adults in an oral presentation.

In a WeChat official account article, Raynovent stated that data showed the RAY1225 18 mg group achieved an average weight reduction of 21.18% over the 24-week treatment period, with 100% of participants experiencing weight loss exceeding 15%.

Raynovent stated that it is accelerating the global clinical development of RAY1225 at full speed. Patient enrollment has been completed for the Phase III weight loss study (REBUILDING-2) and the Phase III glucose-lowering studies (SHINING-2, SHINING-3), and clinical trial applications for the MASH and OSA indications have been approved. In terms of commercialization layout, the company has reached a commercial licensing cooperation agreement with Qilu Pharmaceutical, with a total potential value of up to RMB 1 billion.